Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.45 |
| ▸ | UQCRB | P14927 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28023600 | 0.87 | ALDH1A1 (0.67) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL3723855 | 0.86 | GBA1 (0.70) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL4463262 | 0.86 | GBA1 (0.70) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL3716602 | 0.86 | GBA1 (0.70) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL14132568 | 0.84 | CA1 (0.53) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL3412102 | 0.84 | CA1 (0.52) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL6789995 | 0.84 | CA1 (0.57) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL6321592 | 0.84 | CA1 (0.73) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL6321465 | 0.84 | CA1 (0.52) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL3412348 | 0.84 | CA1 (0.52) | CA1CA2ALDH1A1GBA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
| CN-1238688-A | Thiol sulfonamide metalloprotease inhibitors | MONSANTO CO (US) | 1999-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | CA1 196/4885CA2 492/4885ALDH1A1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.